VITE AB ADR

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, VITE AB ADR has already paid €0.10 in dividends. The last payout was in May.

Financials

In the last quarter, VITE AB ADR had revenue of €76.82M and net profit of €10.95M

(EUR)	September 2026	YoY
Revenue	76.82M	3.21%
Gross profit	39.98M	5.27%
Net profit	10.95M	20.43%
EBITDA	23.81M	4.75%

Fundamentals

Metric	Value
Market capitalization	€1.21B
Number of shares	132.73M
52-week high/low	€16.55 - €8.48
Dividend yield	0.81%
Dividends TTM	€0.10
Beta	1.71
P/E ratio	-3.16
PEG ratio	0.00
P/B ratio	1.91
P/S ratio	4.46

Company profile

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.